Research News
View articles by month and year
11–20 of 29 articles
-
New Guidelines Prefer Aromatase Inhibitors Over Tamoxifen
The American Society of Clinical Oncology has issued new guidelines on taking hormonal therapy medicines after breast cancer surgery.
-
Zometa Before Surgery Doesn’t Seem to Have Benefits
Research shows that Zometa (chemical name: zoledronic acid) doesn't destroy or slow the growth of breast cancer cells when given before surgery to post-menopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.
-
Compared to Tamoxifen, 5 Years of Femara Improves Survival
Taking Femara (chemical name: letrozole) for 5 years as the first adjuvant hormonal therapy medicine improved overall survival by 13% compared to taking tamoxifen for 5 years.
-
Estradiol Therapy May Help Some Advanced-Stage Breast Cancers Start Responding to Hormonal Therapy Again
A small study found that estradiol, a form of estrogen, was an effective treatment for about 30% of advanced-stage, hormone-receptor-positive breast cancers that had stopped responding to hormonal therapy.
-
Femara May Improve Survival Compared to Tamoxifen
For the first time, research suggests that the aromatase inhibitor Femara improves overall survival compared to tamoxifen.
-
Femara and Tykerb Combo Better Than Femara Alone for Metastatic Hormone-Receptor-Positive, HER2-Positive Cancers
A new study shows that treating hormone-receptor-positive, HER2-positive metastatic breast cancer with the combination of Femara and Tykerb offers more benefits than Femara alone.
-
Aromatase Inhibitors Slightly Better Than Tamoxifen for Postmenopausal Women
A review of a number of studies confirms that aromatase inhibitors reduce the risk of early-stage, hormone-receptor-positive breast cancer coming back better than tamoxifen in post-menopausal women.
-
Estradiol May Make Breast Cancer Start Responding to Aromatase Inhibitors Again
A small study found that estradiol, a form of estrogen, can make advanced-stage, hormone-receptor-positive breast cancers that have stopped responding to hormonal therapy start responding again in some cases.
-
Hormonal Therapy Side Effects Linked to Lower Risk of Recurrence
New research suggests a link between hormonal therapy side effects (hot flashes, night sweats, joint pain) and a reduced risk of breast cancer coming back.
-
Femara After Five Years of Tamoxifen Reduces Recurrence Risk
Taking the aromatase inhibitor Femara (chemical name: letrozole) after taking tamoxifen for 5 years reduced the risk of the breast cancer coming back (recurrence), compared to not taking Femara after tamoxifen, even when Femara was started up to 7 years after tamoxifen.
11–20 of 29 articles
